At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
nilotinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center Single Agent Phase II Study of the Efficacy of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor
In Brief
A Phase 2 clinical trial evaluating nilotinib for Pigmented Villonodular Synovitis and 2 related conditions. Completed, enrolled 17 participants across 7 sites.
Detailed Summary
Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS). In this research study the investigators are testing whether nilotinib can stop the growth of PVNS or improve the symptoms experienced from PVNS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, Massachusetts General Hospital, Novartis
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedSep 2010
Primary CompletionApr 2014
Study CompletionAug 2015
TodayJul 2026
First PostedSep 23, 2010
Enrollment StartSep 1, 2010
Primary CompletionApr 1, 2014
Study CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 15.8 years ago
Interventions
nilotinibdrug
Taken orally twice daily